For Healthcare Professionals

Registry of Participants With Generalized Myasthenia Gravis Treated With C5 Inhibition Therapies

clipboard-pencil

About the study

This is a long-term, multicenter, observational registry of participants with generalized myasthenia gravis (gMG) who are treated with Alexion complement C5 inhibition therapies (C5IT) prior to enrollment.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Participants with gMG who have received treatment with Alexion C5IT.
  2. Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions.
  3. Participants must have myasthenia gravis historical data available to be enrolled in the Registry.

EXCLUSION CRITERIA

  1. Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 855-752-2356Email iconEmail Study Center

Study’s details


Contition

Generalized Myasthenia Gravis

Age

18+

Participants needed

500

Est. Completion Date

Nov 2024

Treatment type

Observational [Patient Registry]


Sponsor

Alexion Pharmaceuticals

ClinicalTrials.gov identifier

NCT04202341

Study number

ALXN-MG-501

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.